Johnson & Johnson (JNJ)

139.55
0.35 0.25
NYSE
Prev Close 139.90
Open 139.65
Day Low/High 138.86 / 140.14
52 Wk Low/High 118.62 / 148.99
Volume 3.59M
Exchange NYSE
Shares Outstanding 2662.77B
Market Cap 367.01B
Div & Yield N.A. (N.A)
Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Takeaways and Observations

  Every single market indicator I look at is overbought.  But it's likely that shorts and underperformers are buoying stocks.  Some are at the most overbought in decades.  The bond market is clearly not as sanguine on economic growth/corporate profi...

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra hopes this deal will grow its revenue to $2 billion sooner than expected.

Cramer: Why Are People Dumping Such Good Stocks?

Cramer: Why Are People Dumping Such Good Stocks?

Amazon, J&J, IBM and others don't deserve this treatment.

Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today

Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today

They have become a referendum on Trump's plans for lower corporate taxes.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

My Takeaways and Observations

"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...

Jim Cramer: Johnson & Johnson Will Do Well With Actelion

Jim Cramer: Johnson & Johnson Will Do Well With Actelion

J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.

News Out of Europe: Johnson & Johnson Buys Actelion

News Out of Europe: Johnson & Johnson Buys Actelion

Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.

Johnson & Johnson Buys Actelion for $30 Billion

Johnson & Johnson Buys Actelion for $30 Billion

Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.

Johnson & Johnson Still Too Pricey

Johnson & Johnson Still Too Pricey

The most logical path for Johnson & Johnson in the next 12 months appears to be sideways or down.

Rev's Forum: Sometimes a Breakout is Just a Breakout

Rev's Forum: Sometimes a Breakout is Just a Breakout

Too many traders overthink market action rather than embrace the momentum and look for reasons to enjoy the upside.

Global Stocks Are Following Wall Street Higher as Dow Hits 20,000

Global Stocks Are Following Wall Street Higher as Dow Hits 20,000

The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.

Will Johnson & Johnson's Upside Reversal Last?

Will Johnson & Johnson's Upside Reversal Last?

I'd like to see confirmation of this reversal tomorrow, but now I would "stick my neck out" and write puts.

Cramer: This Rally Is for Real, With Further to Go

Cramer: This Rally Is for Real, With Further to Go

Half the Dow components have reported and it's their impressive results that are driving indices up.

Jim Cramer Looks Beyond Dow 20,000

Jim Cramer Looks Beyond Dow 20,000

Jim Cramer says the Dow hitting 20,000 is different from previous big runs because the milestone comes during earnings season and allows traders to reevaluate.

Closing Bell: Johnson & Johnson Drags on Health Care; S&P 500, Nasdaq at Records

Closing Bell: Johnson & Johnson Drags on Health Care; S&P 500, Nasdaq at Records

The Dow Jones Industrial Average sports double-digit gains for the first time in three weeks, moving it closer to 20,000.

The Market Without Memory From Day to Day

Today's market has ignored disappointing profit results at 3M (down $3), Johnson & Johnson  (down $3) and Verizon  (down $2.50), among others.   The "reflation" trade appears to be back (in part a function of several predictable executive orders by ...

Jim Cramer Says J&J's Quarter Wasn't That Bad, but He Can't Jump on Pharma Stocks Right Now

Jim Cramer Says J&J's Quarter Wasn't That Bad, but He Can't Jump on Pharma Stocks Right Now

Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.

J&J Guides Lower for 2017 Despite Fourth-Quarter Beat

J&J Guides Lower for 2017 Despite Fourth-Quarter Beat

Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.

An Uninspiring Start to the Day

The following companies (hat tip Zero Hedge) missed on the top line (sales) this morning (profits weren't much better): Johnson & Johnson MMM DuPont Kimberly-Clark Verizon Again, for emphasis -- beware of the bullish narrative of an improving profit...

Underperformer J&J Does It Again

Dow Jones Industrial Average member Johnson & Johnson is lower in pre-market trading. The reason? The drug maker took a page out of IBM's playbook by recording a much lower effective tax rate in the quarter (14.5% vs. 18%), which on an adjusted basi...

What to Watch Tuesday: Verizon, Lockheed Martin Report Earnings

What to Watch Tuesday: Verizon, Lockheed Martin Report Earnings

On Tuesday, January 24, investors await a host of quarterly earnings reports.

What to Watch This Week: Trump's Presidency, Alphabet Earnings

What to Watch This Week: Trump's Presidency, Alphabet Earnings

For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Intermediate Trade: Johnson & Johnson

Intermediate Trade: Johnson & Johnson

After an up-and-down year, this household name is as strong as ever.